Allergan makes major urology acquisition
This article was originally published in Scrip
Executive Summary
Allergan has acquired development and commercialization rights to interstitial cystitis/ bladder pain syndrome therapy LiRIS (lidocaine) from Taris Biomedical.
You may also be interested in...
FDA's Advisory Cmte. Meeting On Bladder Pain Syndrome May Signal Policy Changes
The Bone, Reproductive and Urologic Drugs Advisory Committee will consider endpoints, clinical trial designs and other issues related to development in the disease.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.